And Then There Were 4

This year started with just two players in the U.S. drug-eluting stent market -- Johnson & Johnson (NYSE: JNJ  ) and Boston Scientific (NYSE: BSX  ) -- but now the number of competitors has doubled with the addition of Medtronic's (NYSE: MDT  ) Endeavor in February and Abbott Labs' (NYSE: ABT  ) Xience V last week.

The market's reaction was ho-hum -- lifting Abbott less than 1% in Thursday's short trading day. That's what happens when FDA approvals are widely expected after positive advisory panel meetings. But now the fun begins, because we get to see exactly how well the four can compete with each other in a market that's severely shrunk from its heyday.

Medtronic was able to capture an estimated 20% of the U.S. stent market in its first quarter on the market, but I'm not sure if the head start on Abbott is really going to help all that much. Interventional cardiologists are notorious for wanting to try new gadgets -- hence Medtronic's quick market penetration -- so Abbott shouldn't have any problems getting them to try out the Xience.

The competition gets even more complex because the terms of the breakup of Guidant, which sent the Xience to Abbott, allow Boston Scientific to sell the Xience stent under the brand name Promus. It'll be interesting to see how Boston Scientific handles the option of pushing its older Taxus versus the shiny-new Promus. Since it'll have to ship royalties over to Abbott on sales of Promus, you'd think that Boston Scientific's sales reps would want to push the Taxus. But the Xience/Promus beat the Taxus in a head-to-head trial, so the sales reps may not have much of a choice on which one to push.

How much is Abbott going to be able to make off its new stent? I figure it can sell more than Medtronic's run rate of about $325 million per year, but it probably won't come close to taking enough market share to match Boston Scientific's $1 billion in U.S. sales last year -- at least not in its first year on the market. Given that Abbott had almost $26 billion in revenue last year, the sales will be a nice addition, but they won't send the top line to the moon any time soon.

Johnson & Johnson is an Income Investor recommendation. To see how dividend-paying stocks can offer both secure income and the opportunity for growth, take a free look at this newsletter with a 30-day free trial.

Fool contributor Brian Orelli, Ph.D., doesn't own shares of any company mentioned in this article. The Fool has a disclosure policy.

Read/Post Comments (1) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On July 08, 2008, at 2:25 PM, evevevevev wrote:

    Abbotts stent Xience is the same stent that Boston Scientific will be selling called Promus. The only difference is the boxes.

Add your comment.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 679614, ~/Articles/ArticleHandler.aspx, 10/22/2016 8:18:17 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated 11 hours ago Sponsored by:
DOW 18,145.71 -16.64 -0.09%
S&P 500 2,141.16 -0.18 -0.01%
NASD 5,257.40 15.57 0.30%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

10/21/2016 4:00 PM
ABT $40.50 Down -0.24 -0.59%
Abbott Laboratorie… CAPS Rating: *****
BSX $22.82 Down -0.19 -0.83%
Boston Scientific CAPS Rating: ***
JNJ $113.44 Down -1.43 -1.24%
Johnson and Johnso… CAPS Rating: ****
MDT $83.91 Down -0.11 -0.13%
Medtronic CAPS Rating: *****